Primary Image

generic image

Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

IRB Protocol Number STU00219033

Contact

nvg@sralab.org

Objective

This study is examining how the study drug, NVG-291, affects nerve connections in the spinal cord and whether it is safe and tolerable to use.

Volunteers in this study will:

  • Participate in study visits over 16 weeks.
  • Visits will take place at the Shirley Ryan 汤头条app.

Visit involves:  

  • Non-invasive stimulation of the brain and spinal cord and startle acoustic stimuli.
  • Upper and lower limb training
  • Answer questionnaire
  • Physiological and physical assessments
  • Receiving daily injections of NVG-291 or placebo.

Who Can Participate

Participants with a spinal cord injury who are:

  • Between 18-75 years of age 
  • Sustained a spinal cord injury at C1-C7 (1 -10 years post injury) 
  • In good physical health 
  • Proficiency in English

Compensation

Receive compensation

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

More Studies

Research Survey: Answer questions about your experience receiving Home and Community-Based Services (HCBS)

The purpose of this study is to test a set of surveys designed to determine if Home and Community-Based Services (HCBS) are person-centered. Person-centered HCBS are based on what is important to the person receiving the services and are designed to help the recipient live the life they want to live. In order to determine if HCBS are person-centered, a set of surveys has been developed to measure the person-centeredness (or not) of HCBS. You will be helping to see if the surveys measure what they are intended to measure.
You will be asked questions about your daily life and your experience using HCBS.

survey.

read more
view all

Latest Updates

view all